Ratings by Mizuho (Joseph Catanzaro)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (N/A) |
132.55 (132.91) |
0.27% | Details | |
| 6/8/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2026 | Q32 Bio Inc. | QTTB | New Coverage | Outperform (N/A) |
5.67 (13.09) |
130.86% | Details | |
| 5/14/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Upstream Bio | UPB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Avalo Therapeutics Inc. | AVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2026 | Climb Bio | CLYM | New Coverage | Outperform (N/A) |
8.63 (12.90) |
49.48% | Details | |
| 4/14/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2026 | Revolution | RVMD | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/30/2026 | Eikon Therapeutics Inc. | EIKN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Apogee Therapeutics Inc | APGE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Outperform (N/A) |
13.64 (12.54) |
-8.06% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2026 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
12.35 (29.46) |
138.54% | Details | |
| 1/27/2026 | Erasca Inc | ERAS | New Coverage | Outperform (N/A) |
9.96 (18.47) |
85.44% | Details | |
| 1/13/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Upstream Bio | UPB | New Coverage | Outperform (N/A) |
29.32 (7.51) |
-74.39% | Details | |
| 12/18/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Neutral (N/A) |
18.15 (29.00) |
59.78% | Details | |
| 12/18/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
32.97 (86.63) |
162.75% | Details | |
| 12/18/2025 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
18.82 (18.84) |
0.11% | Details | |
| 12/11/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Nurix | NRIX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2025 | Nurix | NRIX | New Coverage | Outperform (N/A) |
9.84 (23.97) |
143.6% | Details | |
| 10/21/2025 | Revolution | RVMD | New Coverage | Outperform (N/A) |
54.10 (189.24) |
249.8% | Details | |
| 10/21/2025 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
26.83 (38.37) |
43.01% | Details | |
| 10/21/2025 | Apogee Therapeutics Inc | APGE | New Coverage | Outperform (N/A) |
55.15 (132.55) |
140.34% | Details | |
| 10/21/2025 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
59.83 (113.51) |
89.72% | Details |
